Veterinary Molecular Biology, Montana State University, Bozeman, MT 59717, USA.
Vaccine. 2010 Apr 19;28(18):3219-30. doi: 10.1016/j.vaccine.2010.02.022. Epub 2010 Mar 1.
The chemokine, lymphotactin (LTN), was tested as a molecular adjuvant using bicistronic DNA vaccines encoding the protective Yersinia capsular (F1) antigen and virulence antigen (V-Ag) as a F1-V fusion protein. The LTN-encoding F1-V or V-Ag vaccines were given by the intranasal (i.n.) or intramuscular (i.m.) routes, and although serum IgG and mucosal IgA antibodies (Abs) were induced, F1-Ag boosts were required for robust anti-F1-Ag Abs. Optimal efficacy against pneumonic plague was obtained in mice i.m.-, not i.n.-immunized with these DNA vaccines. These vaccines stimulated elevated Ag-specific Ab-forming cells and mixed Th cell responses, with Th17 cells markedly enhanced by i.m. immunization. These results show that LTN can be used as a molecular adjuvant to enhance protective immunity against plague.
趋化因子淋巴毒素 (LTN) 被用作双顺反子 DNA 疫苗的分子佐剂进行测试，该疫苗编码保护性的鼠疫耶尔森氏菌荚膜 (F1) 抗原和毒力抗原 (V-Ag)，作为 F1-V 融合蛋白。通过鼻内 (i.n.) 或肌肉内 (i.m.) 途径给予 LTN 编码的 F1-V 或 V-Ag 疫苗，尽管诱导了血清 IgG 和粘膜 IgA 抗体 (Abs)，但需要 F1-Ag 加强以产生强大的抗 F1-Ag Abs。用这些 DNA 疫苗通过肌肉内 (i.m.) 免疫而非鼻内 (i.n.) 免疫的小鼠获得了针对肺鼠疫的最佳疗效。这些疫苗刺激了升高的 Ag 特异性 Ab 形成细胞和混合 Th 细胞反应，通过肌肉内免疫显著增强了 Th17 细胞。这些结果表明 LTN 可用作分子佐剂来增强针对鼠疫的保护性免疫。
